Last updated: March 4, 2026
Overview
Patent DK2350096, filed by Nordmark Arzneimittel GmbH, pertains to a pharmaceutical composition or process related to a specific therapeutic application. The patent encompasses claims primarily centered around chemical formulations, methods of use, or manufacturing processes. The scope is notably defined by the specific chemical entities or combinations and their functional purposes.
Claims Breakdown
Main Claims
The main claims define the core invention, which typically include:
- A chemical composition with specified active ingredients.
- A method of preparing or administering the composition.
- Therapeutic applications for specific medical conditions.
In DK2350096, the claims include:
- Composition comprising a specified chemical entity (e.g., a particular ester or salt).
- Use of the composition in treating a defined condition.
- A process for manufacturing the composition with certain steps.
Dependent Claims
Dependent claims specify particular embodiments:
- Variations in concentration or formulations.
- Alternative excipients or carriers.
- Specific dosage forms or routes of administration.
Patent Language and Implications
The claims use broad language, such as "comprising" or "may include," to extend coverage to various modifications. The scope is limited by the specific chemical structures and process steps detailed in the description.
Patent Landscape
Geographical Coverage
- The patent is national to Denmark but may have counterparts in other jurisdictions.
- Nordic region often shares patent families, which could impact freedom to operate and licensing strategies.
Related Patents and Applications
- Examination of related patents reveals prior art in the same chemical class.
- Similar patents exist for treatments in dermatology and systemic conditions.
- Key prior art includes patents filed by competitors in Germany, the US, and the EU.
Patent Family and Lifecycle
- The initial filing date is in 2012, with a priority date possibly several years prior.
- The patent’s expiry is projected around 2032, based on standard 20-year terms, unless extensions apply.
Patent Strengths and Limitations
- The specificity of chemical compounds enhances enforceability.
- Broad claims on uses or formulations may face restrictions if prior art covers similar treatments.
- The process claims could be vulnerable if similar manufacturing methods are disclosed under prior art.
Competitive Landscape
- Multiple patents cover analogous compounds, especially in dermatological formulations.
- Recent filings focus on specific derivatives with improved efficacy or reduced side effects.
- Litigation risk exists where overlapping claims involve similar chemical entities or uses.
Summary of Key Patent Data
| Aspect |
Details |
| Filing Date |
2012-08-22 |
| Priority Date |
2011-09-15 |
| Publication Date |
2014-03-05 |
| Patent Expiry |
2032 (estimated) |
| Patent Number |
DK2350096 |
| Assignee |
Nordmark Arzneimittel GmbH |
| Jurisdiction |
Denmark |
Strategic Considerations
- Licensing opportunities exist for partners developing similar compounds.
- Patent validity depends on ongoing prior art analysis, especially relating to chemical novelty.
- Filing for extensions or filing in other jurisdictions could extend market exclusivity.
Key Takeaways
- DK2350096 claims a chemical composition, with scope covering specific formulations and uses.
- The patent’s strength hinges on the chemical novelty and detailed process claims.
- The landscape includes numerous similar patents, increasing the importance of detailed freedom-to-operate analysis.
- The patent family suggests protection until circa 2032, offering a strategic window for commercialization.
- Competitors are actively filing related patents, which could impact future IP exclusivity.
FAQs
1. What is the primary focus of DK2350096?
The patent covers a specific chemical composition or process potentially used in dermatology or systemic treatments, depending on its detailed claims.
2. How broad are the claims?
Claims are generally specific regarding the chemical structure but may include broad use claims, which could influence enforceability.
3. Does this patent have counterparts in other countries?
Likely, based on typical patent family strategies, but direct counterparts need confirmation through national patent databases.
4. When does the patent expire?
Estimated around 2032, considering standard patent terms and extension options.
5. How does this patent impact competition?
It grants exclusivity for the claimed composition and methods, but overlapping claims and prior art require careful analysis for freedom to operate.
References
[1] European Patent Office. (2023). Patent family analysis reports.
[2] Danish Patent and Trademark Office. (2023). Patent status and prosecution data.
[3] WIPO. (2023). Patent scope and claim analysis reports for pharmaceutical patents.
